CORDIS
EU research results

CORDIS

English EN

Cancer heterogeneity and therapy profiling using bioresponsive nanohydrogels for the delivery of multicolor logic genetic circuits.

Objective

Conventional cancer therapies suffer from poor efficacy owing to the lack of efficient delivery systems and to the inherent tumor heterogeneity that requires multi-modal approach to abrogate cancer progression. Nanotechnology holds promise to address these drawbacks, as the use of (bio)nanomaterials for diagnostics and therapy has been gaining momentum over the last years. The main goal of this project is to develop a novel and facile platform capable of profiling both the therapy outcome and heterogeneity in cancer, by using bioresponsive nanohydrogels for the delivery of logic multicolor synthetic gene circuits. These logic synthetic gene circuits will be designed as a biobarcode of multicolor RNA circuits embedded in hybrid nanoparticles and doped in hydrogels for local therapy in breast cancer in vivo. Using cell-type specific promoters, the multicolor miRNA circuits will be expressed specifically to each type of the cells of the tumor microenvironment. Subsequently, this will permit to evaluate the therapeutic efficacy in a cell-by-cell basis and to profile the tumor heterogeneity across different breast cancer types. In order to potentiate the translation of this ground-breaking platform into clinics and precision medicine, novel de-regulated miRNA targets will be identified based on screens performed in breast cancer patient-derived tumors that better reflect the heterogeneous tumor microenvironment in a patient-by-patient basis.
In sum, the material platforms developed herein and newly identified biological targets can be harnessed to design effective cancer treatments that go beyond breast cancer. The project is highly versatile and multidisciplinary and this system can be easily adapted to target any cancer cell type and molecular mechanisms and translated to clinical testing.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Address

Avenida Prof Egas Moniz
1649 028 Lisboa

Portugal

Activity type

Research Organisations

EU Contribution

€ 1 435 312

Beneficiaries (1)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Portugal

EU Contribution

€ 1 435 312

Project information

Grant agreement ID: 848325

Status

Grant agreement signed

  • Start date

    1 February 2020

  • End date

    31 January 2025

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 1 435 312

  • EU contribution

    € 1 435 312

Hosted by:

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Portugal